10-Q: TScan Therapeutics Q3 2025: Strategic Shift & Workforce Cut

TScan Therapeutics reports Q3 2025 results, revealing increased losses, a strategic pivot to heme malignancies, and a 30% workforce reduction to extend cash runway into H2 2027.

Summary

• Net loss for the three months ended September 30, 2025, was $35.7 million, compared to $29.9 million for the same period in 2024.
• Net loss for the nine months ended September 30, 2025, was $106.8 million, compared to $91.7 million for the same period in 2024.
• Collaboration and license revenue increased to $2.5 million in Q3 2025 from $1.0 million in Q3 2024, primarily due to the Amgen agreement.
• Research and development expenses rose to $31.7 million in Q3 2025 from $26.3 million in Q3 2024, driven by increased laboratory supplies, research materials, and clinical study activities.
• General and administrative expenses increased to $7.9 million in Q3 2025 from $7.4 million in Q3 2024, mainly due to higher personnel expenses.
• As of September 30, 2025, cash, cash equivalents, and marketable securities totaled $184.5 million (excluding $5.0 million in restricted cash).
• On November 3, 2025, a strategic decision was made to prioritize clinical development of the heme program (TSC-101), pause further enrollment in the solid tumor Phase 1 trial, and focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity.
• This strategic shift included a workforce reduction of approximately 30%, or 66 roles, expected to result in a one-time charge of up to $2.3 million in Q4 2025 for severance-related benefits.
• The company now expects its existing cash, cash equivalents, and marketable securities to fund operations into the second half of 2027.

Sentiment

Score: 3

Explanation: The sentiment is negative due to increased net losses, a significant workforce reduction, and the pausing of a key clinical trial. While the strategic pivot and extended cash runway provide some stability, they are reactive measures to underlying challenges, reflecting a difficult operating environment and early-stage development risks.

Positives

• Collaboration and license revenue significantly increased to $2.5 million in Q3 2025 from $1.0 million in Q3 2024, and to $7.8 million for the nine months ended September 30, 2025, from $2.2 million in the prior year, primarily due to the Amgen agreement.
• Achieved alignment with the U.S. Food and Drug Administration (FDA) on the registrational path forward for the TSC-101 program for AML and MDS, providing a clear development strategy.
• The strategic prioritization and workforce reduction are expected to extend the company's cash runway into the second half of 2027, providing longer financial stability.
• Continued preclinical development in promising areas such as in vivo engineering for solid tumors and target discovery in autoimmunity.

Negatives

• Net loss increased to $35.7 million in Q3 2025 from $29.9 million in Q3 2024, and to $106.8 million for the nine months ended September 30, 2025, from $91.7 million in the prior year.
• Accumulated deficit reached $481.9 million as of September 30, 2025, indicating substantial historical losses.
• Implemented a significant workforce reduction of approximately 30% (66 roles), which may impact employee morale, institutional knowledge, and operational continuity.
• Paused further enrollment in the solid tumor Phase 1 trial, signaling a setback or re-prioritization away from this program.
• Interest and other income, net, decreased by $1.4 million in Q3 2025 compared to Q3 2024, primarily due to lower cash balances available for investment.

Risks

• The company has incurred significant losses since inception and expects to continue incurring losses, with no guarantee of achieving or sustaining profitability.
• Success is highly dependent on the proprietary platform, which represents a novel approach to cancer treatment and faces significant development challenges.
• Limited operating history makes it difficult to evaluate business success and future viability.
• Substantial additional funding will be required to complete product development and commercialization; inability to raise capital could force delays or program elimination.
• Raising additional capital may dilute existing stockholders, restrict operations, or require relinquishing intellectual property rights on unfavorable terms.
• Global economic uncertainty, financial market volatility, and changes in U.S. fiscal/tax policies could adversely affect financing access and business operations.
• Adverse developments in the financial services industry could impact liquidity and access to credit.
• Terms of the loan agreement place restrictions on operating and financial flexibility.
• The recent workforce reduction and strategic prioritization may lead to difficulties in managing operations, loss of expertise, and may not achieve anticipated benefits.
• Preclinical studies and clinical trials may fail to demonstrate adequate safety, potency, and purity, preventing or delaying regulatory approval.
• Product candidates may cause undesirable side effects (e.g., GvHD, autoimmunity, immunogenicity) that could halt development or limit commercial potential.
• Difficulties in enrolling patients in clinical trials could delay development activities.
• Market opportunities for product candidates may be relatively small, and estimates of target patient populations may be inaccurate.
• Significant competition from larger biotechnology and pharmaceutical companies with greater resources.
• Manufacturing and administering product candidates is complex, with potential difficulties in production, process development, and scaling up.
• The regulatory approval process is lengthy and time-consuming, with significant delays possible, and approval in one jurisdiction does not guarantee approval in others.
• Inability to obtain and maintain patent protection or sufficiently broad scope could allow competitors to commercialize similar products.
• Reliance on third parties for clinical trials and manufacturing exposes the company to risks if these parties fail to perform their duties.
• Internal computer systems or those of third parties are vulnerable to cybersecurity incidents, data breaches, or other disruptions.
• Product liability lawsuits could result in substantial liabilities and limit commercialization.
• Ability to utilize net operating loss carryforwards and other tax attributes may be limited by ownership changes.
• The price of common stock is volatile and may decline due to substantial sales by existing stockholders or other market factors.
• Changes in tax legislation, such as the OBBBA, could adversely affect the business and financial condition.
• Business disruptions from natural disasters or other events could seriously harm future revenue and financial condition.

Future Outlook

The company expects to continue incurring significant expenses and increasing operating losses for the foreseeable future. Following a strategic prioritization and workforce reduction, existing cash, cash equivalents, and marketable securities are now projected to fund operations into the second half of 2027. The company plans to further expand its heme program with additional TCRs targeting other HLA types and will focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity. A pivotal study for the TSC-101 program in AML and MDS is planned, mirroring the ongoing Phase 1 study with a biologically-assigned internal control arm to support relapse-free survival as the primary endpoint. The company will need substantial additional funding to complete the development and commercialization of its product candidates.

Management Comments

• "We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future."
• "We believe that our existing cash, cash equivalents and marketable securities will enable us to fund our current operating plan into the second half of 2027."
• "Our approach is based on the central premise that we can learn from patients who are winning their fight against cancer to treat those who are not."

Industry Context

The biotechnology industry is characterized by intense competition, rapid innovation, and significant capital requirements, with larger, more established companies often having greater resources. TScan Therapeutics' focus on novel TCR-T therapy for cancer treatment places it in a high-risk, high-reward segment, facing challenges in regulatory approval, manufacturing scalability, and market acceptance. The increasing regulatory scrutiny on cell and gene therapies, as evidenced by the FDA's dedicated office and recent actions on CAR-T therapies, highlights the evolving landscape. Macroeconomic factors like inflation, rising interest rates, and geopolitical instability are noted as potential headwinds affecting financing access and operating costs across the industry. Changes in U.S. government policies, particularly regarding drug pricing and tax laws, also introduce uncertainty for pharmaceutical and biotech companies.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking against industry standards.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings.

Related Party Transactions

• The company has an amended and restated royalty agreement with one of its founders (assigned to an affiliated entity in January 2021) to pay an aggregate royalty of 1% of net sales of any product covered by a pending patent application or issued patent.

Stakeholder Impact

• **Shareholders:** Face increased dilution risk from future capital raises, potential stock price volatility, and limited influence on corporate matters due to concentrated ownership. Realization of gains relies solely on stock appreciation as no dividends are expected.
• **Employees:** A significant workforce reduction of 30% (66 roles) impacts job security, morale, and potentially leads to loss of institutional knowledge. Remaining employees may experience increased workload and responsibilities.
• **Patients/Customers:** The strategic pivot prioritizes the heme program (TSC-101) for AML/MDS, potentially offering a clearer path to treatment for these patients. However, pausing the solid tumor trial enrollment means delays or cessation of development for patients in that area.
• **Creditors:** The SVB Loan Agreement imposes restrictions on operating and financial flexibility, but the absence of a financial maintenance covenant provides some operational leeway. The extended cash runway improves short-term solvency.
• **Suppliers/Partners:** Continued reliance on third-party manufacturers and suppliers for critical materials introduces supply chain risks. The Amgen collaboration for Crohn's disease target discovery remains active.

Next Steps

• Conduct a pivotal study for the TSC-101 program (AML and MDS) mirroring the ongoing Phase 1 study, using a biologically-assigned internal control arm to support relapse-free survival as the primary endpoint.
• Further expand the heme program with the addition of TCRs targeting other HLA types.
• Focus preclinical efforts on in vivo engineering for solid tumors and target discovery in autoimmunity.
• Continue to discover targets for Crohn's disease in partnership with Amgen.
• Record a one-time charge of up to $2.3 million in the fourth quarter of 2025 for severance-related benefits and other costs associated with the workforce reduction.
• Evaluate the impact of adopting new accounting standards (ASU No. 2023-09, ASU No. 2024-04, ASU No. 2024-03) on consolidated financial statements and disclosures.

Key Dates

Recommendation

The company is navigating a challenging period marked by increased net losses and a significant workforce reduction, which are negative indicators. However, the strategic pivot to prioritize the heme program (TSC-101) with FDA alignment on a registrational path provides a clearer, more focused development strategy. The extended cash runway into the second half of 2027, achieved through cost-cutting, offers crucial time for clinical progress. Given the early-stage nature of biotech, the high burn rate, and the ongoing need for substantial additional capital, the stock remains high-risk. A 'Hold' recommendation acknowledges the recent negative operational news but also recognizes the potential for future value creation if the focused heme program progresses successfully. Investors should closely monitor clinical trial results and future financing activities.

Keywords

TCR-T therapy, TScan Therapeutics, biotechnology, cancer treatment, heme malignancies, solid tumors, TSC-101, AML, MDS, ImmunoBank, clinical trials, FDA, regulatory approval, financial results, Q3 2025, workforce reduction, cash runway, Amgen collaboration, intellectual property, risk management